Xilio Therapeutics Files 8-K on Officer Changes
Ticker: XLO · Form: 8-K · Filed: Apr 16, 2026 · CIK: 0001840233
Sentiment: neutral
Topics: officer-change, filing, exhibits
TL;DR
Xilio Therapeutics filed an 8-K on 4/16/26 about exec changes. No $$ yet.
AI Summary
On April 16, 2026, Xilio Therapeutics, Inc. filed an 8-K report detailing changes in its executive officers and compensatory arrangements. The filing specifically addresses Item 5.02, concerning the departure or election of directors and officers, and Item 9.01, related to financial statements and exhibits. No specific names or dollar amounts were detailed in the provided filing excerpt.
Why It Matters
Changes in executive officers and compensatory arrangements can signal shifts in company strategy, leadership stability, and potential future financial performance.
Risk Assessment
Risk Level: low — The filing is a routine 8-K reporting officer changes and exhibits, with no immediate financial or operational risks indicated.
Key Players & Entities
- Xilio Therapeutics, Inc. (company) — Filer of the 8-K report
- 0001840233 (company) — CIK number for Xilio Therapeutics, Inc.
- 2026-04-16 (date) — Filing date of the 8-K report
- 2026-04-15 (date) — Period of report for the 8-K
FAQ
What specific changes were made regarding directors or certain officers at Xilio Therapeutics, Inc. on April 15, 2026?
The 8-K filing for April 16, 2026, indicates that Item 5.02, concerning the departure of directors or certain officers and election of directors, was addressed. However, the provided excerpt does not detail the specific changes.
What is the significance of Item 9.01 in this 8-K filing?
Item 9.01 pertains to Financial Statements and Exhibits, suggesting that the filing includes or references relevant financial information and supporting documents.
When was this 8-K filing accepted by the SEC?
The 8-K filing was accepted by the SEC on April 16, 2026, at 07:35:16.
What is the CIK number for Xilio Therapeutics, Inc.?
The CIK number for Xilio Therapeutics, Inc. is 0001840233.
What is the business address and contact number for Xilio Therapeutics, Inc.?
The business address for Xilio Therapeutics, Inc. is 828 WINTER STREET WALTHAM MA 02451, and their contact number is 617-833-1027.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 16, 2026 regarding Xilio Therapeutics, Inc. (XLO).